The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction
- 1 October 1990
- journal article
- research article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 163 (4) , 1164-1167
- https://doi.org/10.1016/0002-9378(90)90680-6
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.Journal of Clinical Oncology, 1989
- The CA 125 tumour-associated antigen: a review of the literatureHuman Reproduction, 1989
- Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapyGynecologic Oncology, 1988
- CA 125 Serum Levels Correlated With Second-Look Operations Among Ovarian Cancer PatientsObstetrics & Gynecology, 1986
- Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour markerBritish Journal of Cancer, 1984
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958